Literature DB >> 21282290

Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models.

Johannes Vogel1, Max Gassmann.   

Abstract

As the basic function of erythropoietin (Epo) is stimulation of red blood cell production, systemic overexpression of Epo results in erythrocytosis. The patho-physiological consequences of chronically elevated red blood cell counts have been studied in Epo overexpressing mice. Genetically modified mice, however, have also played an important role in discovering multiple additional functions of Epo besides stimulating erythrocyte production. Non-erythropoietic functions of Epo are widespread and play a role in organogenesis during early embryonic development and in tissue protection in ischaemic diseases. Future work in the field will most likely focus on these additional functions of Epo, which have great clinical potential.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282290      PMCID: PMC3082089          DOI: 10.1113/jphysiol.2010.196147

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  54 in total

1.  Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.

Authors:  F T Ruschitzka; R H Wenger; T Stallmach; T Quaschning; C de Wit; K Wagner; R Labugger; M Kelm; G Noll; T Rülicke; S Shaw; R L Lindberg; B Rodenwaldt; H Lutz; C Bauer; T F Lüscher; M Gassmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.

Authors:  M Ogilvie; X Yu; V Nicolas-Metral; S M Pulido; C Liu; U T Ruegg; C T Noguchi
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice.

Authors:  Kazutaka Ueda; Hiroyuki Takano; Yuriko Niitsuma; Hiroshi Hasegawa; Raita Uchiyama; Toru Oka; Masaru Miyazaki; Haruaki Nakaya; Issei Komuro
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

4.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain.

Authors:  A L Sirén; F Knerlich; W Poser; C H Gleiter; W Brück; H Ehrenreich
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

5.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.

Authors:  A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.

Authors:  Ruben J Boado; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; William M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2010-03-16       Impact factor: 4.030

7.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Authors:  M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  Erythropoietin: not just about erythropoiesis.

Authors:  Pietro Ghezzi; Myrian Bernaudin; Myriam Bernaudinb; Roberto Bianchi; Roberto Bianchic; Klas Blomgren; Michael Brines; Wendy Campana; Guido Cavaletti; Anthony Cerami; Michael Chopp; Thomas Coleman; Murat Digicaylioglu; Hannelore Ehrenreich; Serhat Erbayraktar; Zebeide Erbayraktar; Max Gassmann; Sermin Genc; Necati Gokmen; Giovanni Grasso; Sandra Juul; Stuart A Lipton; Carla Cerami Hand; Roberto Latini; Giuseppe Lauria; Marcel Leist; Samuel Sathyanesan Newton; Edwige Petit; Lesley Probert; Alessandra Sfacteria; Anna-Leena Siren; Mark Talan; Chris Thiemermann; Daan Westenbrink; Magdi Yaqoob; Changlian Zhu
Journal:  Lancet       Date:  2010-06-19       Impact factor: 79.321

9.  Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin.

Authors:  Hiroto Ueba; Michael Brines; Michael Yamin; Tomio Umemoto; Junya Ako; Shin-ichi Momomura; Anthony Cerami; Masanobu Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

10.  Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

Authors:  Angus M Sinclair; Angela Coxon; Ian McCaffery; Stephen Kaufman; Katherine Paweletz; Liqin Liu; Leigh Busse; Susan Swift; Steven Elliott; C Glenn Begley
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

View more
  18 in total

1.  Elevated haematocrit - when too much of a good thing wreaks havoc on the endothelial surface layer.

Authors:  Roland N Pittman
Journal:  J Physiol       Date:  2011-11-15       Impact factor: 5.182

Review 2.  Red blood cell volume and the capacity for exercise at moderate to high altitude.

Authors:  Robert A Jacobs; Carsten Lundby; Paul Robach; Max Gassmann
Journal:  Sports Med       Date:  2012-08-01       Impact factor: 11.136

3.  Synthesis, function and possible new avenues for erythropoietin.

Authors:  Carsten Lundby
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

4.  Excessive erythrocytosis compromises the blood-endothelium interface in erythropoietin-overexpressing mice.

Authors:  Vincent Richter; Michele D Savery; Max Gassmann; Oliver Baum; Edward R Damiano; Axel R Pries
Journal:  J Physiol       Date:  2011-08-22       Impact factor: 5.182

5.  Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.

Authors:  Elena Gammella; Victor Diaz; Stefania Recalcati; Paolo Buratti; Michele Samaja; Soumyadeep Dey; Constance Tom Noguchi; Max Gassmann; Gaetano Cairo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-12-17       Impact factor: 3.619

6.  Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival.

Authors:  Carolina Purroy; Robert L Fairchild; Toshiaki Tanaka; William M Baldwin; Joaquin Manrique; Joren C Madsen; Robert B Colvin; Alessandro Alessandrini; Bruce R Blazar; Miguel Fribourg; Chiara Donadei; Umberto Maggiore; Peter S Heeger; Paolo Cravedi
Journal:  J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 10.121

Review 7.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

8.  Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice.

Authors:  Victor Samillan; Thomas Haider; Johannes Vogel; Caroline Leuenberger; Matthias Brock; Colin Schwarzwald; Max Gassmann; Louise Ostergaard
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

9.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.

Authors:  Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2018-07-02       Impact factor: 3.657

Review 10.  Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration.

Authors:  Hal E Broxmeyer
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.